In this episode of the Journal of Gynecologic Oncology Podcast, we discuss a recent study by Kristin Bixel and colleagues on the use of adjuvant hormone therapy in patients with early-stage low-grade endometrial stromal sarcoma. Using data from the National Cancer Database, the study analyzed over two thousand patients and found that while the use of hormonal therapy has increased over time, it does not improve overall survival. We explore key findings, clinical implications, and the need for further research on recurrence prevention and quality of life. Tune in for an in-depth discussion, and Happy Lunar New Year to our listeners!

Adjuvant hormone therapy and overall survival among low-grade and apparent early-stage endometrial stromal sarcoma patients (https://doi.org/10.3802/jgo.2025.36.e50)